Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss
Go back to Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss| (NASDAQ: ZEAL) | Delayed: 17.59 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.59 | 52 Week High | $ | |||
| Open | $1.35 | 52 Week Low | $ | |||
| Day High | $17.59 | P/E | N/A | |||
| Day Low | $17.59 | EPS | $ | |||
| Volume | 15,962 | |||||
